NanoViricides, Inc. Advances MPox Drug Development Amid WHO's Extended Health Emergency

NanoViricides, Inc. (NYSE American: NNVC), a leader in the development of host-mimetic nanomedicine, has reaffirmed its commitment to combating the MPox virus following the World Health Organization's (WHO) decision to extend the Public Health Emergency of International Concern (PHEIC). The company's focus is on NV-387, a broad-spectrum antiviral drug that has successfully completed Phase I trials, demonstrating a strong safety profile, and is now moving towards Phase II trials in Africa. This development comes at a critical time as the global community seeks effective treatments against MPox, with existing options like tecovirimat and brincidofovir showing limitations in efficacy and safety.

NV-387 stands out due to its innovative approach; it mimics human cell features to prevent viral entry, a mechanism that could potentially circumvent the issue of viral resistance. This unique property not only positions NV-387 as a promising candidate for MPox treatment but also opens up opportunities for its application in other viral infections. The advancement of NV-387 into Phase II trials is a significant milestone for NanoViricides, Inc., as it paves the way for the drug's potential inclusion in government bioterrorism stockpiles, tapping into multi-billion-dollar markets.

The WHO's extension of the PHEIC underscores the persistent threat posed by MPox and the urgent need for effective therapeutics. NanoViricides, Inc.'s progress with NV-387 offers hope for a new treatment option that could significantly impact the global response to MPox and similar viral threats. The company's dedication to advancing NV-387 through clinical trials reflects its commitment to addressing unmet medical needs and contributing to global health security.